| Literature DB >> 35090165 |
Paul R Wratil1,2, Marcel Stern1, Alina Priller3, Annika Willmann4, Giovanni Almanzar5, Emanuel Vogel4, Martin Feuerherd4, Cho-Chin Cheng4, Sarah Yazici3, Catharina Christa4, Samuel Jeske4, Gaia Lupoli1, Tim Vogt5, Manuel Albanese1, Ernesto Mejías-Pérez1, Stefan Bauernfried6, Natalia Graf4, Hrvoje Mijocevic4, Martin Vu4, Kathrin Tinnefeld4, Jochen Wettengel2,4, Dieter Hoffmann2,4, Maximilian Muenchhoff1,2, Christopher Daechert1, Helga Mairhofer1, Stefan Krebs7, Volker Fingerle8, Alexander Graf7, Philipp Steininger9, Helmut Blum7, Veit Hornung6, Bernhard Liebl8, Klaus Überla9, Martina Prelog5, Percy Knolle10,11, Oliver T Keppler12,13,14, Ulrike Protzer15,16.
Abstract
Infection-neutralizing antibody responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 vaccination are an essential component of antiviral immunity. Antibody-mediated protection is challenged by the emergence of SARS-CoV-2 variants of concern (VoCs) with immune escape properties, such as omicron (B.1.1.529), which is rapidly spreading worldwide. Here we report neutralizing antibody dynamics in a longitudinal cohort of coronavirus disease 2019 convalescent and infection-naive individuals vaccinated with mRNA BNT162b2 by quantifying SARS-CoV-2 spike protein antibodies and determining their avidity and neutralization capacity in serum. Using live-virus neutralization assays, we show that a superior infection-neutralizing capacity against all VoCs, including omicron, developed after either two vaccinations in convalescents or a third vaccination or breakthrough infection of twice-vaccinated, naive individuals. These three consecutive spike antigen exposures resulted in an increasing neutralization capacity per anti-spike antibody unit and were paralleled by stepwise increases in antibody avidity. We conclude that an infection-plus-vaccination-induced hybrid immunity or a triple immunization can induce high-quality antibodies with superior neutralization capacity against VoCs, including omicron.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35090165 DOI: 10.1038/s41591-022-01715-4
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440